Intracranial meningiomas represent the most frequent primary central nervous system neoplasms encountered in clinical practice. While many patients present with benign, asymptomatic tumors, complicated lesions require nuanced microsurgical techniques and rigorous perioperative care. An extensive nationwide cohort study published in the Journal of Neuro-Oncology evaluates how surgical volume directly impacts intracranial meningioma outcomes. Consequently, evaluating institutional patterns provides vital clinical insights for neurosurgeons, oncologists, and healthcare leaders seeking to standardize high-quality cranial care.

Evaluating Hospital Volume and Intracranial Meningioma Outcomes

The relationship between institutional operative caseload and therapeutic success remains a central focus of modern surgical oncology. In this extensive investigation, researchers analyzed records from 181,401 patients treated for intracranial meningioma across the United States between 2004 and 2019. The study team defined high-volume facilities as institutions performing forty-five or more meningioma procedures each year. Notably, this operational threshold captured the top fifteen percent of healthcare centers nationwide. Within this expansive cohort, 28,325 patients received care at high-volume facilities, while 153,076 patients underwent treatment at lower-volume institutions. Multivariable logistic regression and adjusted Cox proportional hazards models allowed investigators to determine the true association between facility volume and survival. Furthermore, the statistical models controlled for critical patient characteristics, including baseline age, systemic comorbidity indices, and specific tumor histological grades. As a result, the authors eliminated confounding variables that frequently bias retrospective surgical comparisons. Therefore, this rigorous database analysis delivers reliable clinical evidence regarding the profound protective effect of institutional procedural volume. Neurosurgical teams at specialized centers regularly execute complex operative plans with greater consistency and lower technical morbidity. Ultimately, surgical volume serves as an essential surrogate marker for institutional infrastructure, technical proficiency, and comprehensive care pathways.

Disparities in Access to High-Volume Neurosurgical Centers

Despite the demonstrated advantages of high-volume care, patient access to specialized institutions remains markedly unequal. Multivariable regression analyses demonstrated that insurance coverage significantly influenced where patients received surgical care. Specifically, individuals with private insurance coverage had twenty-five percent higher odds of undergoing resection at high-volume centers compared to uninsured or Medicaid recipients. Moreover, higher household income, younger age, and metropolitan residence strongly correlated with admission to high-volume institutions. Conversely, patients from rural communities or economically disadvantaged areas presented predominantly to lower-volume local hospitals. In addition, patients presenting with higher Charlson-Deyo comorbidity scores received care more frequently at low-volume facilities. These demographic and financial patterns highlight persistent systemic inequities in neuro-oncological care distribution. Consequently, vulnerable populations often miss opportunities to receive centralized surgical interventions and advanced post-resection therapies. Addressing these disparities requires targeted administrative reforms, transparent referral guidelines, and expanded transportation resources for underserved regional populations. Furthermore, clinician awareness regarding regional disparities can prompt proactive patient navigation and timely transfers. Therefore, health systems must intentionally eliminate structural barriers to ensure equitable specialty access for every neurosurgical candidate.

Surgical Expertise and Multimodal Treatment Strategies

Specialized centers maintain advanced infrastructure that directly alters clinical management strategies for patients with intracranial meningioma. Notably, high-volume institutions treated a substantially larger share of anatomically challenging, invasive, or high-grade meningiomas. Because high-volume centers routinely manage complex skull base tumors, their surgical teams utilize cutting-edge operative microscopes, continuous intraoperative neuro-monitoring, and stereotactic neuronavigation. Furthermore, specialized institutions utilize comprehensive multimodal management paradigms far more consistently than lower-volume centers. For instance, tertiary teams frequently incorporate adjuvant stereotactic radiosurgery and intensity-modulated radiation therapy for atypical, malignant, or subtotal resections. In contrast, low-volume community facilities rely primarily on standalone resection or passive surveillance, which can lead to delayed recurrence management. Additionally, high-volume centers conduct weekly multidisciplinary neuro-oncology boards that unite neurosurgeons, neuropathologists, radiation oncologists, and neuro-radiologists. As a result, patients receive coordinated care plans tailored to their specific tumor molecular profile and anatomical features. Consequently, institutional caseload directly enriches collective surgical judgment and technical refinement. Ultimately, this comprehensive multidisciplinary approach minimizes unexpected treatment complications while ensuring robust local disease control and neurological preservation.

Overall Survival Advantages at High-Volume Facilities

The multivariable survival analysis demonstrated a profound survival benefit for individuals undergoing meningioma resection at high-volume facilities. After fully adjusting for baseline demographics, systemic comorbidities, and tumor histological characteristics, treatment at high-volume centers remained an independent predictor of decreased mortality. Log-rank testing verified that patients managed at high-volume institutions experienced significantly improved overall survival compared to those treated at low-volume centers. Conversely, patients treated at lower-volume hospitals experienced higher rates of perioperative complications and shortened survival times. Multiple clinical mechanisms likely drive this durable survival advantage. First, experienced neurosurgeons achieve higher rates of safe maximal resection while preserving critical cranial nerves and cerebral vasculature. Second, specialized neuro-intensive care units possess dedicated clinicians who expertly detect and manage brain edema, cerebrospinal fluid leaks, and intracranial hemorrhages. Moreover, dedicated nursing teams implement aggressive mobilization protocols that lower the incidence of deep vein thrombosis and pulmonary complications. Ultimately, high procedural volume fosters institutional resilience and superior rescue capabilities during acute postoperative crises. Therefore, institutional volume serves as a protective factor against both early perioperative death and late tumor-related mortality.

Clinical Implications for Health Systems and Referrals

These comprehensive findings offer actionable lessons for clinical practitioners, hospital administrators, and healthcare policymakers across the globe. Because initial surgical management dictates long-term prognosis, clinical teams should consider early referral for complex meningiomas. Primary care physicians and general neurosurgeons should establish streamlined referral agreements with regional high-volume tertiary centers. Similarly, hospital administrators must construct hub-and-spoke delivery networks that concentrate difficult skull base operations in experienced regional centers. Meanwhile, community hospitals can safely manage straightforward, non-skull base convexities that carry minimal operative risk. However, when diagnostic imaging reveals skull base involvement, sinus invasion, or significant mass effect, immediate tertiary consultation remains paramount. Furthermore, national healthcare planners must expand health insurance coverage to eliminate the financial disparities that prevent equitable access to specialized neurosurgery. In summary, centralized surgical care and standardized multidisciplinary management together represent the optimal strategy for improving intracranial meningioma outcomes. By fostering regional collaboration, health systems can systematically elevate standards of patient care and surgical safety. Consequently, healthcare stakeholders should actively align health policies with this robust clinical evidence to enhance neuro-oncological survival.

How does institutional volume directly improve intracranial meningioma outcomes?

High-volume institutions provide superior outcomes through extensive surgical expertise, dedicated neurocritical care units, and routine multidisciplinary tumor boards. Operative teams achieve higher rates of safe tumor resection while minimizing neurological deficits. Furthermore, standardized postoperative protocols in high-volume settings significantly reduce perioperative mortality, wound complications, and unplanned hospital readmissions for patients.

What annual procedural threshold defines a high-volume neurosurgical facility?

In the National Cancer Database analysis, researchers defined a high-volume facility as an institution performing forty-five or more intracranial meningioma procedures per year. This operational cutoff represented the top fifteen percent of healthcare centers nationwide, distinguishing specialized academic and tertiary cancer centers from community and lower-volume regional hospitals.

Which patients with intracranial meningioma benefit most from tertiary referral?

Patients presenting with complex skull base tumors, atypical or anaplastic histopathological features, recurrent disease, or substantial medical comorbidities benefit most from tertiary referral. These challenging cases require specialized microsurgical skull base techniques, advanced intraoperative cranial nerve monitoring, and tailored adjuvant stereotactic radiotherapy coordinated by multidisciplinary neuro-oncology teams.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

Horowitz MA et al. The association of hospital volume status with treatment and survival outcomes of intracranial meningioma patients: a multivariable analysis of the National Cancer Database. J Neurooncol. 2025 Jul. doi: 10.1007/s11060-025-05011-2. PMID: 40153120.

Goldbrunner R, Stavrinou P, Jenkinson MD, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021;23(11):1821-1834.